Information Provided By:
Fly News Breaks for February 19, 2016
RARE
Feb 19, 2016 | 06:33 EDT
Leerink analyst Joseph Schwartz started Ultragenyx with an Outperform rating and $80 price target. The company is positioned well to "leverage the key advantages inherent" in the rare disease space, Schwartz tells investors in a research note.
News For RARE From the Last 2 Days
There are no results for your query RARE